ArticleCancer immunology, immunotherapy : CII2012
Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK).
Article in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Interactions Between Endogenous Opioids and the Immune System.Advances in neurobiology · 2024Review
- The Opioid Growth Factor in Growth Regulation and Immune Responses in Cancer.Advances in neurobiology · 2024Article
- Knowledge Mapping of Opioids and Immunomodulation: A Bibliometric Analysis (2000-2022).Journal of pain research · 2023Article
- Endogenous Opioids and Their Role in Stem Cell Biology and Tissue Rescue.International journal of molecular sciences · 2022Review
- Review
- Expression of Opioid Receptors in Cells of the Immune System.International journal of molecular sciences · 2020Review
- Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer.Current treatment options in oncology · 2020Review
- The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin.Cancer management and research · 2018Article
- A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2).Human vaccines & immunotherapeutics · 2015Article
- Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+Foxp3+ regulatory T cells (Tregs) in mice.Cancer biology & therapy · 2015Article
- Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs).Human vaccines & immunotherapeutics · 2014Article
- Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs).Human vaccines & immunotherapeutics · 2013Article
- Methionine enkephalin (MENK) improved the functions of bone marrow-derived dendritic cells (BMDCs) loaded with antigen.Human vaccines & immunotherapeutics · 2012Article
- The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: pidotimod(PTD).Human vaccines & immunotherapeutics · 2012Article
- Opioid System Modulates the Immune Function: A Review.Translational perioperative and pain medicineArticle
Corrections and comments
- Erratum issuedLiu, Jingling [corrected to Liu, Jinling]
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methionine enkephalin (MENK), the endogenous neuropeptide, is known to exert direct effects on the neuroendocrine and the immune systems and participates in regulation of various functions of cells related to both the innate and adaptive immune systems. Dendritic cells (DCs) play important role in initiating and regulating T cell responses. The aim of this work is to investigate the effects of MENK on differentiation, maturation, and function of DCs derived from murine bone marrow progenitors (BM-derived DCs). Our result showed that MENK could induce BM-derived DCs to polarize predominantly to mDC subtype, rather than pDC both in vivo and in vitro, and this was in favor of Th1 response. BM-derived DCs, after treatment with MENK, up-regulated the expressions of MHC class II and key costimulatory molecules. Result by RT-PCR showed MENK could increase expressions of delta and kappa receptors on BM-derived DCs. Also MENK promoted BM-derived DCs to secret higher levels of proinflammatory cytokines of IL-12p70, TNF-α. Furthermore, differentiated BM-derived DCs treated with MENK displayed higher activity to induce allogeneic T cell proliferation and MENK also inhibited tumor growth in vivo and induced apoptosis of tumor cells in vitro. Thus, it is concluded that MENK could be an effective inducer of BM-derived DCs and might be a new therapeutic agent for cancer, as well as other immune handicapped disease. Also we may consider MENK as a potential adjuvant in vaccine preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.